Eli Lilly and Co (XSWX:LLY) Owner Earnings per Share (TTM): 11.50 (As of Mar. 2026) — 81% Below Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XSWX:LLY Eli Lilly and Co XSWX:LLY
99 GF Score
Price CHF940.00
GF Value CHF1,133.72
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is Eli Lilly and Co Owner Earnings per Share (TTM)?

Eli Lilly and Co XSWX:LLY 99 Owner Earnings per Share (TTM) is 11.50 as of Mar. 2026, which is 81% below its 10-year median of 59.71. GuruFocus rates XSWX:LLY with a GF Score™ of 99/100 and a GF Value™ of CHF1,133.72 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 475 Drug Manufacturers companies, Eli Lilly and Co ranks worse than 84.21% on this metric.

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Eli Lilly and Co's Owner Earnings per Share (TTM) ended in Mar. 2026 was CHF11.50. It's Price-to-Owner-Earnings ratio for today is 81.74.


The historical rank and industry rank for Eli Lilly and Co's Owner Earnings per Share (TTM) or its related term are showing as below:

XSWX:LLY' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 17.09   Med: 59.71   Max: 1489.69
Current: 81.76


During the past 13 years, the highest Price-to-Owner-Earnings ratio of Eli Lilly and Co was 1489.69. The lowest was 17.09. And the median was 59.71.


XSWX:LLY's Price-to-Owner-Earnings is ranked worse than
84.21% of 475 companies
in the Drug Manufacturers industry
Industry Median: 24.46 vs XSWX:LLY: 81.76

Eli Lilly and Co's Earnings per Share (Diluted) for the three months ended in Mar. 2026 was CHF6.50. Its Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was CHF22.45. It's PE Ratio (TTM) ratio for today is 41.87.

Eli Lilly and Co's EPS without NRI for the three months ended in Mar. 2026 was CHF6.73. Its EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 was CHF23.47. It's PE Ratio without NRI ratio for today is 40.04.


Be Aware

Assumption: Companies usually do not report maintenance capital expenditures and growth capital expenditures separately. Here we use estimated numbers and average them over 5 years. The method to estimate maintenance capital expenditures can be found in above part 4.

Note: GuruFocus' Change In Working Capital is provided by Morningstar. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement from original financial report. And it includes non-current parts of assets and liabilities.


Eli Lilly and Co Owner Earnings per Share (TTM) Related Terms


Eli Lilly and Co Owner Earnings per Share (TTM) Historical Data

* Premium members only.

The historical data trend for Eli Lilly and Co's Owner Earnings per Share (TTM) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Eli Lilly and Co Owner Earnings per Share (TTM) Chart

Eli Lilly and Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Owner Earnings per Share (TTM)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.26 3.94 -1.18 0.55 6.78

Eli Lilly and Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Owner Earnings per Share (TTM) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.18 0.54 5.94 6.78 11.19

XSWX:LLY vs JNJ, ABBV, MRK: Owner Earnings per Share (TTM) Comparison

For the Drug Manufacturers - General subindustry, Eli Lilly and Co's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Eli Lilly and Co Price-to-Owner-Earnings vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Eli Lilly and Co's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Eli Lilly and Co's Price-to-Owner-Earnings falls into.


XSWX:LLY
99GF Score
Eli Lilly and Co XSWX:LLY
Owner Earnings per Share (TTM) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Eli Lilly and Co Owner Earnings per Share (TTM) Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

To make it simple, then you will have:

Owner Earnings per Share (TTM) = (Net Income + Depreciation, Depletion and Amortization + Change In Deferred Tax - 5Y Average of Maintenance Capital Expenditure + Change In Working Capital) / Shares Outstanding (Diluted Average)

Eli Lilly and Co's Owner Earnings per Share (TTM) Calculation:

TTM / Last Quarter Average of Last 20 Quarters
Net Income 20,160
Depreciation, Depletion and Amortization 1,631
Change In Deferred Tax -2,229
5Y Average of Maintenance Capital Expenditure 4,782
Change In Working Capital -5,116
Shares Outstanding (Diluted Average) 896

1. Start with "Net Income" from income statement. Eli Lilly and Co's Net Income for the trailing twelve months (TTM) ended in Mar. 2026 was CHF20,160 Mil.

2. "Depreciation, Depletion and Amortization" is from cashflow statement. Eli Lilly and Co's Depreciation, Depletion and Amortization for the trailing twelve months (TTM) ended in Mar. 2026 was CHF1,631 Mil. This needs to be added back because company does not actually need to pay cash for it. It is a non-cash item.

3. Other non-cash charges usually include "Stock Based Compensation" and "Change In Deferred Tax":
However, to be conservative, GuruFocus will not add Stock Based Compensation back to net income. Eli Lilly and Co's Change In Deferred Tax for the trailing twelve months (TTM) ended in Mar. 2026 was CHF-2,229 Mil.

4. Average maintenance capital expenditure over a business/industry cycle: 5-Year Average Maintenance Capital Expenditure = CHF4,782 Mil

It is usually best to take a long-term average of maintenance capital expenditure. Ideally this would be as long as 10 years and include at least one economic downturn. However, since many companies do not have as long as 10-year history, here GuruFocus uses the latest 5 years data to do the calculation. To smooth out unusual years but reflect recent developments, we take an average of the 5 year maintenance capital expenditure.

The following shows how to get maintenance capital expenditure.

First, calculate the revenue change regarding to the previous quarter. If the revenue decreased from the previous quarter, then the Maintenance Capital Expenditure = Capital Expenditure (positive).
Second, if the revenue increased from the previous quarter, then calculate the percentage of Net PPE as of corresponding Revenue.
Growth Capital Expenditure = Percentage of Property, Plant and Equipment as of corresponding Revenue * Revenue Increase
Third, calculate Capital Expenditure (positive) - Growth Capital Expenditure.
If [Capital Expenditure (positive) - Growth Capital Expenditure] was negative, then the Maintenance Capital Expenditure = Capital Expenditure (positive).
If [Capital Expenditure (positive) - Growth Capital Expenditure] was positive, then the Maintenance Capital Expenditure = Capital Expenditure (positive) - Growth Capital Expenditure.
Fourth, get the average of the 5 years maintenance capital expenditure.

Eli Lilly and Co's 5-Year Average Maintenance Capital Expenditure = CHF4,782 Mil

5. "Change In Working Capital" is from cashflow statement. Eli Lilly and Co's Change In Working Capital for the trailing twelve months (TTM) ended in Mar. 2026 was CHF-5,116 Mil.
Note: GuruFocus' Change in Working Capital is provided by Morningstar. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement from original financial report. And sometimes it includes non-current parts of assets and liabilities.

6. Eli Lilly and Co's Shares Outstanding (Diluted Average) for the months ended in Mar. 2026 was 895.900 Mil.

Eli Lilly and Co's Onwer Earnings Per Share for Mar. 2026 is calculated as:

Owner Earnings per Share (TTM)
=( Net Income+Depreciation, Depletion and Amortization+Change In Deferred Tax
=( 20159.801 +1630.601+-2229.367
-5Y Avg of Maintenance CAPEX+Change In Working Capital )/Shares Outstanding (Diluted Average)
-4781.9698635403+-5116.462)/895.900
=11.50

Price-to-Owner-Earnings=Current Price/Owner Earnings per Share (TTM)
=940.00/11.50
=81.74

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Owner Earnings per Share (TTM) of 11.50 mean?
Eli Lilly and Co (XSWX:LLY) has a Owner Earnings per Share (TTM) of 11.50 as of Mar. 2026. Warren Buffett defined owner earnings as reported earnings plus depreciation less average maintenance capital expenditure. View historical data on Eli Lilly and Co. This is 81% below median its historical median of 59.71. Over the past decade, Eli Lilly and Co's Owner Earnings per Share (TTM) has ranged from 17.09 to 1,489.69. According to the industry distribution chart, Eli Lilly and Co ranks #400 out of 475 companies in the Drug Manufacturers industry, placing it in the top 84.2%.
Is Eli Lilly and Co's Owner Earnings per Share (TTM) too high?
Eli Lilly and Co's current Owner Earnings per Share (TTM) of 11.50 is 81% below median its 10-year median of 59.71. Over the past 10 years, this metric has ranged from a low of 17.09 to a high of 1,489.69. The Drug Manufacturers industry median Owner Earnings per Share (TTM) is 24.46. Eli Lilly and Co's value of 11.50 is 53% below this industry median. Based on the distribution chart, Eli Lilly and Co ranks #400 out of 475 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Eli Lilly and Co has a GF Score™ of 99/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Eli Lilly and Co's Owner Earnings per Share (TTM) compare to JNJ and ABBV?
According to the Drug Manufacturers industry distribution chart, Eli Lilly and Co ranks #400 out of 475 companies for Owner Earnings per Share (TTM). This places Eli Lilly and Co in the lower half of its industry. The industry median Owner Earnings per Share (TTM) is 24.46. Eli Lilly and Co's value of 11.50 is 53% below this benchmark. Historically, Eli Lilly and Co's own Owner Earnings per Share (TTM) has ranged from 17.09 to 1,489.69 over the past decade. While the company's 10-year median is 59.71 vs. the industry median of 24.46, Eli Lilly and Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Owner Earnings per Share (TTM) for a Drug Manufacturers company?
The median Owner Earnings per Share (TTM) among Drug Manufacturers companies is 24.46, based on 475 companies in the industry. Companies in the top quartile (top 25%) have a Owner Earnings per Share (TTM) significantly above this median, while those in the bottom quartile fall well below. However, Owner Earnings per Share (TTM) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Eli Lilly and Co's current Owner Earnings per Share (TTM) of 11.50 is 53% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Owner Earnings per Share (TTM) mean?
A high Owner Earnings per Share (TTM) can signal that a stock is expensive relative to its fundamentals. Warren Buffett defined owner earnings as reported earnings plus depreciation less average maintenance capital expenditure. View historical data on Eli Lilly and Co. For the Drug Manufacturers industry, the median Owner Earnings per Share (TTM) is 24.46 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Eli Lilly and Co's current Owner Earnings per Share (TTM) is 11.50, which is 81% below median its own 10-year median of 59.71. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Eli Lilly and Co stock overvalued right now?
Based on GuruFocus' analysis, Eli Lilly and Co (XSWX:LLY) is currently considered Modestly Undervalued. The stock's GF Value™ is CHF1,133.72, compared to a current price of CHF940.00 — trading 17.1% below its estimated fair value. The current Owner Earnings per Share (TTM) is 11.50, which is 81% below median its 10-year median of 59.71 and 53% below the Drug Manufacturers industry median of 24.46. Eli Lilly and Co's overall GF Score™ is 99/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Owner Earnings per Share (TTM) calculated?
Owner Earnings per Share (TTM) is calculated from a company's financial statements. For Eli Lilly and Co (XSWX:LLY), the current Owner Earnings per Share (TTM) is 11.50 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Eli Lilly and Co (XSWX:LLY) Overvalued in 2026?

Based on GuruFocus' analysis, Eli Lilly and Co stock appears to be undervalued. The current stock price of CHF940.00 is trading 17.1% below its estimated GF Value™ of CHF1,133.72. GuruFocus considers Eli Lilly and Co to be Modestly Undervalued.

Key valuation signals for XSWX:LLY:

  • Owner Earnings per Share (TTM): 11.50 (81% below median its 10-year median of 59.71)
  • GF Value™: CHF1,133.72 vs. price of CHF940.00 (17.1% below fair value)
  • GF Score™: 99/100 with 4 warning signs
  • Industry Position: 53% below the Drug Manufacturers median (#400 of 475)

No single metric tells the full story. See the XSWX:LLY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Eli Lilly and Co Business Description

Address Lilly Corporate Center, Indianapolis, IN, USA, 46285
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio and Jaypirca for cancer; Mounjaro, Zepbound, Foundayo, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
99GF Score

Get the complete analysis for XSWX:LLY

Owner Earnings per Share (TTM) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF940.00
Price
CHF1,133.72
GF Value